A further report on the results of EORTC trial 26951 indicates that CpG island methylator phenotype (CIMP) status and O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as assessed by MGMT-STP27 are the most informative for identifying grade III glioma patients who might benefit...
Breast cancer patients over the age of 60 with early-stage, hormone-responsive small tumors who forego adjuvant endocrine, also called hormonal therapy, are not at an increased risk of mortality compared to women of the same age without breast cancer, according to a study published Aug. 31 in...
Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA...
Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer. In the first head-to-head adjuvant clinical trial comparing two aromatase inhibitors, anastrozole...